Natural genetic variations, or polymorphisms, in the ACE gene do not account for the large variability in disease course,…
Ana Pena, PhD
Ana is a molecular biologist with a passion for discovery and communication. As a science writer she looks for connecting the public, in particular patient and healthcare communities, with clear and quality information about the latest medical advances. Ana holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in genetics, molecular biology, and infectious diseases.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Ana Pena, PhD
Amicus Therapeutics and the Perelman School of Medicine at the University of Pennsylvania have expanded their research…
Amicus Therapeutics announced positive preclinical data showing that its investigational gene therapy…
Immunomodulation Plus Myozyme May Help Infants with Pompe Disease, But Seen to Carry Risks in Study
Adding immunomodulatory medicines to enzyme replacement therapy (ERT) — Myozyme (alglucosidase alfa) — gives temporary…